Royce & Associates LP Buys 69,766 Shares of Establishment Labs Holdings Inc. $ESTA

Royce & Associates LP increased its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 24.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 358,541 shares of the company’s stock after purchasing an additional 69,766 shares during the quarter. Royce & Associates LP’s holdings in Establishment Labs were worth $26,130,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Tejara Capital Ltd grew its position in Establishment Labs by 31.2% during the 3rd quarter. Tejara Capital Ltd now owns 102,494 shares of the company’s stock worth $4,201,000 after acquiring an additional 24,386 shares during the last quarter. William Blair Investment Management LLC grew its position in Establishment Labs by 17.6% during the 3rd quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock worth $41,709,000 after acquiring an additional 152,299 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Establishment Labs by 59.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 115,876 shares of the company’s stock worth $8,445,000 after acquiring an additional 43,164 shares during the last quarter. Bamco Inc. NY grew its position in Establishment Labs by 30.2% during the 3rd quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock worth $48,443,000 after acquiring an additional 274,287 shares during the last quarter. Finally, Portolan Capital Management LLC grew its position in shares of Establishment Labs by 24.7% in the 3rd quarter. Portolan Capital Management LLC now owns 155,096 shares of the company’s stock worth $6,357,000 after buying an additional 30,704 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Wall Street Zen lowered Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Friday, March 27th. Canaccord Genuity Group lifted their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Stephens lifted their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Mizuho lifted their price objective on Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.14.

Establishment Labs Price Performance

Shares of ESTA stock opened at $72.64 on Wednesday. The firm has a market cap of $2.14 billion, a P/E ratio of -48.75 and a beta of 1.12. Establishment Labs Holdings Inc. has a fifty-two week low of $33.35 and a fifty-two week high of $83.31. The business’s 50 day moving average price is $64.95 and its 200-day moving average price is $68.33. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The company’s revenue for the quarter was up 44.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.70) EPS. On average, equities research analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Insider Activity at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the transaction, the director owned 927,504 shares in the company, valued at $69,952,351.68. This trade represents a 10.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders sold 330,000 shares of company stock valued at $22,854,538. Company insiders own 9.99% of the company’s stock.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.